LONDON, UK – December 16, 2014 – Immodulon Therapeutics today announced that Orphan designation EU/3/14/1385 was granted by the European Commission for IMM-101, heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer.
LONDON, UK – December 16, 2014 – Immodulon Therapeutics today announced that Orphan designation EU/3/14/1385 was granted by the European Commission for IMM-101, heat-killed Mycobacterium obuense (whole cell) for the treatment of pancreatic cancer.